259 related articles for article (PubMed ID: 12070449)
21. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
22. [Cardiotoxicity of continuous intravenous infusion of 5-fluorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases].
de Forni M; Bugat R; Sorbette F; Delay M; Bachaud JM; Chevreau C
Bull Cancer; 1990; 77(5):429-38. PubMed ID: 2205312
[TBL] [Abstract][Full Text] [Related]
23. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease.
Tsibiribi P; Descotes J; Lombard-Bohas C; Barel C; Bui-Xuan B; Belkhiria M; Tabib A; Timour Q
Bull Cancer; 2006 Mar; 93(3):E27-30. PubMed ID: 16567310
[TBL] [Abstract][Full Text] [Related]
24. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
25. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers.
Yeh KH; Cheng AL; Lin MT; Hong RL; Hsu CH; Lin JF; Chang KJ; Lee PH; Chen YC
Anticancer Res; 1997; 17(5B):3867-71. PubMed ID: 9427794
[TBL] [Abstract][Full Text] [Related]
27. Endothelin-1 and 5-fluorouracil-induced cardiotoxicity.
Porta C; Moroni M; Ferrari S; Nastasi G
Neoplasma; 1998; 45(2):81-2. PubMed ID: 9687887
[TBL] [Abstract][Full Text] [Related]
28. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
[TBL] [Abstract][Full Text] [Related]
29. A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
Villar-Grimalt A; Candel MT; Massuti B; Lizón J; Sánchez B; Frau A; Gorostidi B; Goedkoop R
Br J Cancer; 1999 May; 80(5-6):786-91. PubMed ID: 10360656
[TBL] [Abstract][Full Text] [Related]
30. The need for routine monitoring of cardiac function in patients receiving 5-fluorouracil infusion.
Francis N
Clin J Oncol Nurs; 2014 Jun; 18(3):360-2. PubMed ID: 24867118
[TBL] [Abstract][Full Text] [Related]
31. Is 5-fluorouracil-induced vasospasm a Kounis syndrome? A diagnostic challenge.
Karabay CY; Gecmen C; Aung SM; Guler A; Candan O; Batgerel U; Kalayci A; Kirma C
Perfusion; 2011 Nov; 26(6):542-5. PubMed ID: 21628340
[TBL] [Abstract][Full Text] [Related]
32. [Cardiotoxicity of 5-fluorouracil].
Teixeira L; Barry S; Debourdeau P; Cohen A; Tournigand C
Bull Cancer; 2004 Nov; 91 Suppl 3():154-8. PubMed ID: 15899622
[TBL] [Abstract][Full Text] [Related]
33. Capecitabine cardiotoxicity--case reports and literature review.
Manojlovic N; Babic D; Stojanovic S; Filipovic I; Radoje D
Hepatogastroenterology; 2008; 55(85):1249-56. PubMed ID: 18795667
[TBL] [Abstract][Full Text] [Related]
34. Toxicity of 5-fluorouracil.
Macdonald JS
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):33-4. PubMed ID: 10442356
[TBL] [Abstract][Full Text] [Related]
35. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
Saif MW; Garcon MC; Rodriguez G; Rodriguez T
In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
[TBL] [Abstract][Full Text] [Related]
36. [Extended reversible global left ventricular contraction dysfunction with symptomless coronary system as effect of cytostatic therapy with 5-fluorouracil].
Unverdorben M; Birkenhake S; Kunkel B; Dunst J
Strahlenther Onkol; 1994 Aug; 170(8):461-6. PubMed ID: 8085212
[TBL] [Abstract][Full Text] [Related]
37. Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report.
Akpek G; Hartshorn KL
Cancer Chemother Pharmacol; 1999; 43(2):157-61. PubMed ID: 9923822
[TBL] [Abstract][Full Text] [Related]
38. A Case of 5-Fluorouracil-Induced Cardiac Arrest.
Ray JC; Cho P; Dragon M; Graham CG
J Emerg Med; 2016 Jan; 50(1):e1-6. PubMed ID: 26482827
[TBL] [Abstract][Full Text] [Related]
39. Cardiotoxicity of 5-fluorouracil.
Alter P; Herzum M; Soufi M; Schaefer JR; Maisch B
Cardiovasc Hematol Agents Med Chem; 2006 Jan; 4(1):1-5. PubMed ID: 16529545
[TBL] [Abstract][Full Text] [Related]
40. A new perspective on cardiotoxicity of 5-fluorouracil. A novel research tool 'cardiac ultrasonic integrated backscatter analysis' indicates transient, subclinical myocardial dysfunction due to high-dose leucovorin and infusional 5-fluorouracil regimen.
Barutca S; Ceyhan C; Meydan N; Ozturk B; Tekten T; Onbasili A; Kadikoylu G; Bolaman Z
Chemotherapy; 2004 Jun; 50(3):113-8. PubMed ID: 15272225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
